Dahan Michel 4
4 · Akebia Therapeutics, Inc. · Filed Mar 3, 2023
Insider Transaction Report
Form 4
Dahan Michel
SVP, Chief Business Officer
Transactions
- Sale
Common Stock
2023-03-01$0.88/sh−10,476$9,193→ 271,393 total - Sale
Common Stock
2023-03-01$0.88/sh−1,878$1,648→ 269,515 total - Sale
Common Stock
2023-03-01$0.88/sh−8,058$7,071→ 281,869 total
Footnotes (3)
- [F1]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2022.
- [F2]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 28, 2020.
- [F3]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the performance-based restricted stock units that were previously reported for the Reporting Person on a Form 4 filed on March 18, 2021.